Recommended dose reductions of TAZVERIK® for adverse reactions1
DOSE REDUCTION |
DOSAGE |
---|---|
First | 600 mg twice daily |
Second | 400 mg twice daily* |
*Permanently discontinue TAZVERIK in patients who are unable to tolerate 400 mg orally twice daily.1
Recommended dosage modifications of TAZVERIK for adverse reactions1
ADVERSE REACTION |
SEVERITY |
DOSAGE MODIFICATION |
---|---|---|
Neutropenia | Neutrophil count less than 1 x 109/L |
|
Thrombocytopenia | Platelet count less than 50 x 109/L |
|
Anemia | Hemoglobin less than 8g/dL |
|
Other adverse reactions | Grade 3 |
|
Grade 4 |
|
ADVERSE REACTION & SEVERITY |
DOSAGE MODIFICATION |
---|---|
Neutropenia Neutrophil count less than 1 x 109/L |
|
Thrombocytopenia Platelet count less than 50 x 109/L |
|
Anemia Hemoglobin less than 8 g/dL |
|
Other adverse reactions Grade 3 |
|
Other adverse reactions Grade 4 |
|
Review the Select Lab Abnormalities table when considering dose modifications for adverse reactions.
Recommended dose reductions of TAZVERIK for moderate CYP3A inhibitors, where coadministration cannot be avoided1
CURRENT DOSAGE |
ADJUSTED DOSAGE |
---|---|
800 mg orally twice daily | 400 mg orally twice daily |
600 mg orally twice daily | 400 mg for first dose and 200 mg for second dose |
400 mg orally twice daily | 200 mg orally twice daily |
DOSE ADJUSTMENTS ARE NOT RECOMMENDED FOR PATIENTS WITH: |
---|
|
|
DOSE ADJUSTMENTS ARE NOT RECOMMENDED FOR PATIENTS WITH: |
---|
|
|
†Mild=total bilirubin > 1 to 1.5 times ULN or AST > ULN; moderate=total bilirubin > 1.5 to 3 times ULN; severe=total bilirubin > 3 times ULN.1
CYP3A=Cytochrome P450 (CYP)3A; ULN=upper limit of normal; AST=aspartate aminotransferase.
Reference: 1. TAZVERIK (tazemetostat) Prescribing Information. Cambridge, MA: Epizyme, Inc., July 2020.